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The use of intelligent techniques in medicine has brought a ray of hope in terms of treating leukaemia patients. Personalized
treatment uses patient’s genetic profile to select a mode of treatment.This process makes use of molecular technology and machine
learning, to determine the most suitable approach to treating a leukaemia patient. Until now, no reviews have been published from
a computational perspective concerning the development of personalized medicine intelligent techniques for leukaemia patients
using molecular data analysis. This review studies the published empirical research on personalized medicine in leukaemia and
synthesizes findings across studies related to intelligence techniques in leukaemia, with specific attention to particular categories
of these studies to help identify opportunities for further research into personalized medicine support systems in chronic myeloid
leukaemia. A systematic search was carried out to identify studies using intelligence techniques in leukaemia and to categorize
these studies based on leukaemia type and also the task, data source, and purpose of the studies. Most studies used molecular data
analysis for personalized medicine, but future advancement for leukaemia patients requires molecular models that use advanced
machine-learning methods to automate decision-making in treatment management to deliver supportive medical information to
the patient in clinical practice.
1. Introduction
Molecular cytogenetics of hematological malignancies and
therapies is under development. Leukaemia is a hematolog-
ical disorder where two leukaemia patients who may appear
identical morphologically may have different molecular pro-
files and thus the variation in response to the prescribed
therapies would be unpredictable [1]. Leukaemia usually
begins in the bone marrow, which is the site where all blood
cells are formed andproduced.When a personhas leukaemia,
the white blood cells produced are usually numerous, and
they are abnormal, which means that they cannot effec-
tively defend the body from diseases, pathogens, or foreign
substances. The type of white blood cells affected, either
lymphoid or myeloid, can identify the type of leukaemia.
Four common types of leukaemia are chronic lymphocytic
leukaemia (CLL), chronic myeloid leukaemia (CML), acute
lymphocytic leukaemia (ALL), and acute myeloid leukaemia
(AML) [2].
The most common modes of treatment for leukaemia
involve chemotherapy, radiation therapy, stem cell trans-
plantation, and immunotherapy with interferon [2]. Many
patients become disease-free after years of treatment, pro-
ceeding to live normal lives. However, these modes of
therapy can have disastrous consequences for the victims of
leukaemia. For instance, chemotherapy often makes patients
lose their hair, it can darken their skin, and it can cause
infertility in young patients. Bone marrow transplantation is
also very expensive, and it is not often easy to find amatching
bone marrow donor, especially if close family members
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are not a match. The pharmacogenomics (PGx) aims to
replace general modes of treatment, such as chemotherapy
and bone marrow transplantation, adopting instead a tailor-
made course of medication designed according to a patient’s
particular genetic makeup [3]. Although multiple targeted
therapies are available to use for leukaemia patients [4], it is
difficult to select among the available targeted therapies.
Therefore, the use of intelligent techniques in medicine
has brought a ray of hope in terms of treating leukaemia
patients. Intelligent techniques are able to conduct automatic
searches to discover knowledge and learn from data to
facilitate the task and achieve the objective. The broad
areas frequently defined under intelligence techniques are
as follows: knowledge discovery, machine learning, and
data mining. These areas use statistics and probability to
detect patterns that are difficult to study manually. Intelligent
techniques will integrate various molecular technologies and
sources of data, information, or knowledge to facilitate the
development of personalized medicine and decision-making
by physicians.
The personalized decision support system requires per-
sonal information or genetic information, such as genetic
tests and medical tests, for each patient to integrate, as far
as possible, the knowledge gained from genomics research
relating to the disease in question [5]. From this definition,
it is clear that the need for personalized decision support
systems in leukaemia treatment has increased because of
the massive amount of available genetic and genomic infor-
mation. With the use of the personalized medicine support
system, leukaemia treatment will no longer be a trial and
error game and it will be possible to select which drugs will
work at which stage. The outcomes are expected to provide
a preventive, next-generation therapy, with better specific
interventions for individual patients.
Personalized medicine support systems can use avail-
able knowledge resources to deliver just-in-time informa-
tion to individualize therapy. The existing pharmacoge-
nomics knowledge base (PharmGKB) (available at http://
www.pharmgkb.org) is a massive resource that provides
researchers with information relevant to genetic variations
on drug responses. The second source is to translate PGx
knowledge into a rule-based representation where the rules
are extracted from the characteristics of PGx knowledge in
the US Food and Drug Administration (FDA) drug label
database [6]. Another knowledge resource is the Clinical
Practice Guidelines (CPG) document, which lists a set of
guidelines for cases with specific diagnoses, along with
recommended therapeutic action plans [7].
Developing personalized medicine support systems in
some medical applications has already made significant
progress. First, in cardiovascular diseases, many factors could
influence cardiovascular disease, such as genes, environment,
and lifestyle (exercise and nutrition). It was important to
develop models for prevention, treatment management, or
detecting disease to assist clinicians in treating cardiovas-
cular patients. Indeed, the personalized decision support
system for cardiovascular patients was constructed using two
models. One model was for risk assessment using patients’
personal information, and the other was for generating
advice to clinicians based on the first model’s results [8].
The second application was in type 1 diabetes mellitus. The
frequentmeasurements of glucose levels,monitoring physical
activity, and personal information about the genome, such
as the genes that could cause obesity and predisposition for
diabetes, were used to create a personalized decision support
system for treating, preventing, and monitoring patients [9].
Another system for optimizing insulin infusion rates based
on nonlinear model predictive control was designed using
in silico data from a virtual type 1 diabetes patient, where
the system was evaluated using data from a mathematical
model of a patient with type 1 diabetes. The results showed
the effectiveness of using suchmethodswith diabetes patients
[10]. The third application is colon cancer, where selection
of the treatment plan was the objective of the personalized
medicine support system. The clinical and genomic features
were used for early diagnosis in colon cancer using cluster
techniques. The platform known as MATCH supported clin-
icians in making decisions about patients with colon cancer
[11]. Adding genetic features improves diagnosis compared
to previous research methods. Further methods proposed
for colon cancer prediction based on genetic information
were studied by Kulkarni et al. [12]. The last example, but
not limited to those mentioned in our review, breast cancer
classification is an active research application in which the
personalized medicine support medicine was the objective in
multiple studies [13–31].
One angle of personalized medicine is to identify the
correct disease subtype and patient classification. Machine-
learning techniques were proven to achieve a high perfor-
mance classification in identifying patient subtypes by using
a support vector machine (SVM) and uncertainty SVM [32],
in predicting drug sensitivity in cancer by using Bayesian
networks [33, 34], in predicting patient response to therapy
by using ensemble methods [13], in predicting risk category
using soft computing methods [35], or in recommendations
to enhance lifestyle and educate patients about healthy solu-
tions [36]. Thus, intelligent methods should be proposed to
create a personalized medicine support system in leukaemia.
These methods required information about preknowledge in
allocating optimal treatment, responding to each patient’s
risk category, which should be provided to evaluate the
models.
Medical researchers continue to emphasise that their
studies are updated with the most effective treatment pro-
tocols, which could be used to treat leukaemia patients.
The current system for achieving personalized medicine in
leukaemia has been established by using the predictive factors
to determine upfront treatment. Many groups of researchers
have conducted studies by using different techniques to inves-
tigate several factors that could affect the drug responses.
Studying a single biomarker as a predictive substance could
indicate the response pretreatment and predict the risk to
the individual [37]. The other approach involves predicting
the drug reaction in terms of toxicity or resistance, using
an individual’s genotype data and clinical data to improve
the individual’s care [38]. A pharmacogenetics is a field
that studies the individual’s response to a specific therapy
based on the person’s genotype information.With the human
BioMed Research International 3
molecular tests and the development of molecularly targeted
therapy, the system for achieving personalized medicine for
leukaemia has additional levels of information that needs to
be processed with assistance from information technology.
According to current knowledge, many leukaemia re-
searchers have applied intelligent techniques, but no review-
ers have yet undertaken a systematized literature review from
a computational perspective concerning the development of
personalized medicine intelligent techniques for leukaemia
patients using molecular data analysis. This review studies
the published empirical research on personalizedmedicine in
leukaemia and synthesizes findings across studies related to
intelligence techniques in leukaemia, with specific attention
to particular categories of these studies to help identify oppor-
tunities for further research into personalized medicine sup-
port systems in one category of leukaemia, namely, chronic
myeloid leukaemia. A systematic search was carried out to
identify studies using intelligence techniques in leukaemia
and to categorize these studies based on leukaemia type
and also the task, data source, and purpose of the studies.
Our review is conducted to support health informatics and
biomedical and bioinformatics in order to answer specific
technical questions to help develop future research into
leukaemia from a technical perspective.
2. Methods
2.1. Search Strategy. Ten databases were searched, including
Scopus, PubMed, Web of Science, BIOSIS, Inspec, MED-
LINE, Embase, Springer, ACM Digital Library, and IEEE
Xplore.The review was restricted to English-language studies
published from 2001 to October 2016 because, prior to 2001,
molecular targeted therapies and molecular responses for
personalized medicine were not approved by the FDA for
medical treatments in leukaemia but became more popular
around this time [39]. The search was limited to primary
research articles. The eligibility of each study was evaluated
based on the title and abstract. Only full-text articles were
retrieved.The terms searchedwere leukaemia and leuk∗, with
different combinations of key words for intelligent systems
and techniques (machine learning, data mining, knowledge
extraction, and CDS system) and with combined keywords
and/or subject headings to identify technical leukaemia
articles. Since studies were screened by a single researcher
and then reviewed by the coauthors, this work cannot be
considered a systematic review, but it could be considered
a “systematized review” [40] to demonstrate comprehensive
search guidelines and an elaborative quality assessment and
synthesis of research evidence.
2.2. Selection of Studies and Data Extraction. The resulting
abstracts were evaluated for inclusion. Then, the full text of
those identified asmeeting the criteria were obtained. Studies
were included in the review, if the study
(i) used molecular data from adult leukaemia patients;
(ii) used intelligence techniques to achieve the purpose of
the study;
(iii) was implemented as a model for adult leukaemia
patients;
(iv) was published in a peer-reviewed journal between
2001 and 2016;
(v) was published in English.
Because the intention was to review the literature to
identifywhether opportunities currently under clinical devel-
opment are related to model analysis molecular data for
personalized medicine in leukaemia, articles were excluded,
if they
(1) published decision-analytic models for economic
purposes;
(2) used pediatric leukaemia data;
(3) studied a nonpatient population;
(4) were not written in English;
(5) were doctoral dissertations or pilot studies;
(6) did not include the full text of the study report.
3. Results
3.1. Study Selection. In total, 𝑛 = 1,929 citations were
retrieved. Excluding duplicates, the search yielded 𝑛 = 1,747
articles, and the initial screen of abstracts yielded 𝑛 = 745
articles to undergo a full-text review. Ultimately, 55 studies
met the eligibility criteria and underwent data extraction and
analysis (Figure 1).
55 studies described 55 unique intelligent techniques
(Table 2). The studies were analyzed based on the leukaemia
type involved in the study, the task, the data source, and the
purpose of the study.
3.2. Based on Leukaemia Type. Of the commonest leukaemia
types (Figure 2) involved in previous studies, AML and ALL
occupied most of the classification studies because the DNA
microarray data can be downloaded online from the Cancer
Program Legacy Publication Resources [41].
Some studies [42–44] distinguished ALL origin cell lines
from non-ALL leukaemia origin cell lines. A study [45]
demonstrated a decision support system that classifies all four
types of leukaemia using principal components for feature
selection and clustering. A few studies involved chronic
leukaemia types to identify themolecular biomarker in CML.
For example, Oehler et al. [46] used Bayesian model aver-
aging, while Yeung et al. [47] integrated expert knowledge
to predict the functional relationships in gene expression.
The capture of disease pathophysiology across patient types
was studied by Savvopoulos et al. [48], and temporally and
spatially distributed models were built to extract knowledge
from CLL patients’ blood samples. In CML and CLL studies,
some studies were not included in the final selection because
most of these studies were prospective studies ending with
a description of patient population outcomes, rather than
building models or using intelligent techniques. A study of
combined prognostic markers using a multivariate model for
knowledge extraction is included in this study because it
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Figure 1: Flow chart showing the article-selection process.
























Figure 2: Summary of the frequency of studies based on leukaemia
type.
proved that integration of gene expression in a model can
predict outcomes in CLL [49].
Emphasis has been placed on CML as a research oppor-
tunity because of developments in monitoring CML patients’
molecular response to molecular targeted therapy. The Aus-
tralian Institute of Health and Welfare (AIHW) classified
myeloid cancers as the 9thmost commonly diagnosed cancer
in 2016, with around 3,624 cases in Australia [50]. Chronic
myeloid leukaemia is also known as chronic myelogenous
leukaemia or chronic granulocytic leukaemia. White blood
cells are affected when the bone marrow produces an
unusual number of white blood cells. These cells enter the
bloodstream and accumulate in organs such as the spleen
or liver. If the disease progresses, the bone marrow could
produce an excessive number of immature white blood cells.
Consequently, the bone marrow cannot make enough red
cells, normal white cells, and platelets [51].
In CML, according to White and Hughes [52], the
previous studies did not establish criteria for selecting the
best molecular targeted therapy for each patient, particularly
following the availability of multiple therapies that can rep-
resent a perfect application of personalized therapy based on
predicting patients’ molecular response to molecular target
therapy.
3.3. Based on Data Source. Microarray technology is an area
of considerable focus for the purpose of cancer diagnosis
(Figure 3). One study [45] used exon arrays to classify
patients who suffer from different forms of leukaemia at
various stages. Another study used human leukaemia tissue
to determine different cluster differentiation (CD) markers
[53]. Although seven existing studies used bone marrow cell
images to classify leukaemia subtype, microarrays are still
used to facilitate different types of experiments and clarify the
results, making it easy for researchers to propose molecular
medicines in contrast to the rate of tumor progression.
The other example used gene-expression profiling among
adult patients, which proved crucial in treating leukaemia.
The researchers stated that, with the help of expression
profiling, doctors are able to determine how a patient adapts
to treatment methods. In addition, based on these facts, a
physician is able to determine the survival probability of the
patients in question.
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Figure 3: Summary of the frequency of studies based on data
sources.
A huge opportunity arises from integrating data sources
such as image data, clinical data, lifestyle or family his-
tory, SNP, gene-expression profiles, proteomics profiles, and
metabolomics profiles. For example, SNPs have been inves-
tigated in an attempt to determine the susceptibility rate of
patients suffering from leukaemia, which can support cases
where patients have been diagnosed with leukaemia. The use
of SNPs made it possible for physicians to predict the likely
survivability of their patients after treatment, which is useful
in determining the most suitable medical interventions.
In terms of patient care and administration, electronic
health records (EHR) are often reused in research to answer
specific research questions [5, 54–56]. Cases are matched
with enquiries based on obtained research criteria for patient
inclusion, and a dataset of many matches can then be
generated for analysis. The EHR may include sparse data
or missing values, as some patients may not seek frequent
care. The quality of EHR would likely impact the bias of
research findings or modeling performance. Derivation of
key variables is also an important aspect when dealing
with EHR, as the values may be recorded in different ways
in different systems. This arises due to varying definitions
between sources. The quality of data and correct values
of derived key variables are of concern to researchers, but
many algorithms can be investigated during preprocessing
procedures to improve the quality of data, which would
possibly lead to more reliable results [57].
Yu et al. [58] also divided the source of data and
knowledge into three sources: clinical trial, systems biology,
and healthcare systems. The meta-analysis and systematic
reviews from published clinical trials are themain sources for
gathering data and knowledge, although these methods have
limitations over time. The difficulty of refining knowledge
as new knowledge arises is an issue, as is the length of time
required to build a knowledge base using systematic review
and meta-analysis. The second source is system biology. The
huge amount of data and knowledge collected as panomics
for oncology patients come from genomics, transcriptomics,
proteomics, and metabolomics data. For example, the Global
Alliance for Genomics and Health [59] provides terabytes of
genomic and clinical data for researchers. The third source is
healthcare systems that provide knowledge in digital formats.
The other important source that has not attracted much
interest in leukaemia studies is the data resulting from clin-
ical trials studying healthy populations or epidemiological
studies. Future development of clinical decisions can be
guided by lessons learned from previous trials. Late-phase
clinical trials (phases II, III, and IV) are considered to be
massive sources of information that can be used to build
personalized models. There is also a rapid increase in the
number of electronicmedical research databases that provide
an opportunity for researchers to reuse medial data to create
mathematical models.
The NCI [60] is a US agency that lists ongoing clinical
trials that are testing molecular target therapies, including
most of the studies conducted by investigators at hospitals
and medical centers. The NCI offers full trial descriptions
and names of principal investigators, so researchers can
contact investigators and collaborate to conduct the proposed
research.
The issue with the clinical trial data that it may be biased
in several aspects: sampling, referral, selection, method, and
clinical spectrum biases. Clinical trials may use sampling
methods, sample size, and inclusion and exclusion criteria.
Another aspect is referral bias where patients are referred
by specialists and the data will represent preselected patients
who have high prevalence of disease. Selection bias is clear
when the clinical trial data includes groups based on a variety
of demographics. In the method aspect, the data may be col-
lected using different measurements, which leads to varying
precision and specifications. Finally, the clinical spectrum
bias represented in patient records may show other medical
problems apart from the disease [61]. For instance, Saussele
and Pfirrmann [62] have reported clinical trials in CML.They
demonstrated several aspects that may cause challenges to
reusing clinical trials. According to Saussele and Pfirrmann,
the definition of “remission” varies in clinical trials by
major molecular response (MMR) or complete cytogenetic
response (CCR). In addition, the clinical trials used different
primary endpoints such as 12 months’ MMR or 12 months’
CCR to judge treatment success. The American Society of
Hematology (ASH) has established annual meetings to dis-
cuss medical trial outcomes. In 2006, the 48th ASH Annual
Meeting [63] displayed a poster about the International
Randomized Study of Interferon versus Imatinib STI571
(IRIS) trial. This study showed that Imatinib is appropriate
for CML patients in the chronic phase as results indicate
that patients receiving long-term (5-6 years) Imatinib therapy
achieve MMR in 90% of cases [64]. For CML patients, these
results show the efficacy of continuing to receive Imatinib
over time. In 2010, two significant medical trials, DASISION
(Dasatinib versus Imatinib Study in Treatment-Na¨ıve CML)
and ENESTnd (Evaluating Nilotinib Efficacy and Safety in
Clinical Trials-Newly Diagnosed Patients), were discussed
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at the 52nd Annual Meeting [65]. In DASISION [66], 259
patients were studied for their response to 100mg Dasatinib
once daily versus 260 patients who consumed 400mg of
Imatinib once daily. The MMR was lower for the Imatinib
set compared to the Dasatinib set. The most important result
was the safety profiles of these drugs, which were similar.
The ENESTnd trial focused on the comparison of Nilotinib
versus Imatinib [67]. The samples were newly diagnosed
CML-CP patients. In the trial, 282 patients were given 300mg
Nilotinib twice daily, 281 patients received 400mg Nilotinib
once daily, and 283 patients received 400mg Imatinib once
daily; the median follow-up for these patients was 18 months.
The cytogenetic response (CCyR) and MMR were lower
in patients treated with Imatinib than in patients treated
with Nilotinib. From these trial results, the debate about
selecting the optimal TKI to achieve optimal patient response
has been established with recognition of the need for a
predictive assay that could predict the patient’s response to
initial treatment. The researchers also recognize the need for
a medical trial to compare each TKI against the others as
a first-generation treatment. The introduction of molecular
targeted drugs (TKIs) has led to a dramatic improvement
in the lifespan of patients affected by this condition. With
the three common TKIs, Imatinib, Nilotinib, and Dasatinib
currently approved to use as frontline therapy, an important
question arises regarding which TKI should be prescribed.
White and Hughes [52] stated that, with the lack of clear
recommendations about which TKI to select, clinicians may
prescribe a particular TKI based on their own preference. It
is possible to extract knowledge and modeling systems using
medical data and knowledge in leukaemia, but it requires
advanced computational methods, such as intelligent sys-
tems. Using the available data and knowledge to construct
a personalized medicine support system for leukaemia may
providemassive amounts of information to use for evaluating
therapies and also for potential diagnostic and prognostic
markers.
3.4. Based on the Purpose of the Studies. Medical research
studies have several purposes, including classification of
cancer types or distinguishing healthy cells from unhealthy
cells for the purpose of diagnosis, identifying markers to
help in the management of treatment, and determining the
prognosis of risk. Managing leukaemia patients has gained
attention since a successful study by Alvey et al. [68], who
developed an expert system by using a tree-structured logical
program and produced over 700 clinical diagnostic rules.
Even though this study focused on a specific diagnostic
aspect of the system, another study [69] provided information
for managing patients from registration to diagnosis and
through follow-up after treatment. The study integrated his-
tory, physical examinations, and laboratory data to develop
a decision support system for leukaemia diagnostics. Chae
et al. [69] used profiles from patients admitted to Severance
Hospital in Seodaemun District, Republic of Korea, and
used data from over 490 patients to discover knowledge that
helped physicians in decision-making. There is some evi-
dence that interdisciplinary cooperation between biologists,
medical scientists, computer scientists, and engineers can be
























Figure 4: Summary of the frequency of studies based on the purpose
of the studies.
productive. However, this research team did not incorporate
molecular data in their system.
Among the 55 studies (Figure 4), the common purpose
for conducting the studies was classifying the cancer type
or subtype, with the aim of diagnosing leukaemia patients.
An identifying marker in support of treatment management
was observed in 11 studies. The other purpose for conducting
the studies was using intelligent techniques and statistical
methods for prognosis [70–73]. For example, predicting a
relapse prior to transplantation in CML by integrating iter-
ative Bayesian model averaging includes expert knowledge
and expected functional connections in expression analyses
in order to recognize genes causative of CML evolution [47].
This kind of model provides high-quality results, especially
in complex diseases, but has varying levels of classification
precision.
A new development is to extract relationships between
biomarkers and the outcome in leukaemia patients. Focusing
on CML, a predictive factor is a patient characteristic used
to predict response to treatment [74]. The predictive factors
related to the MMR response include common molecular
assays. Other factors depend on peripheral blood counts as
well as on the molecular-based and clinical observations of
individual patients. In order to select the most effective TKI
therapy at the time of diagnosis, various predictive factors
in CML have been investigated to distinguish patients at an
increased risk of failure with Imatinib, the first-generation
TKI [52, 75–77]. Table 1 shows the current predictive assays
and score systems, the factors included in the score systems
and the methods used, the target prediction, and the pub-
lished results.
Many studies [77, 129] have shown that predictive factors
could probably assist in predicting patient response. Milo-
jkovic et al. [129] conducted their study in order to predict
success or failure of treatment with second-generation TKIs
in CML patients using univariate analyses. They analyzed
a cohort of 80 CML patients in the first chronic phase
who were treated with Dasatinib or Nilotinib. Their score
system predicted the probability of CML patients achieving
a CCR. The system was based on three factors: cytogenetic
BioMed Research International 7
Table 1: The current methods used to identify risk in CML.
Previous methods
Study Factors Method Target prediction Data and results
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response to Imatinib, Sokal score, and recurrent neutropenia
during Imatinib treatment. Although this study used simple
statistical methods, the system succeeded in classifying three
risk categories: good, intermediate, and poor risk. In addition,
Jabbour et al. [77] also studied the factors for predicting 123
CML patients’ response after Imatinib failure. The variables
used in this study included sex, CML duration, months’
performance status, splenomegaly, prior interferon therapy,
peripheral blood, bone marrow, best cytogenetic response to
Imatinib, second-generation Nilotinib or Dasatinib therapy,
active disease at the start of the second course of TKIs,
clonal evaluation, higher than 90% Ph positivity, and IC50
for Nilotinib and Dasatinib for in vitro inhibition of kinase
activity of the mutated point in BCR-ABL. They also used
univariate and multivariate analyses, such as the logistic
regression model and the Cox proportional hazard model,
in order to identify prognostic factors associated with MCyR
and survival, and they succeeded in identifying three risk
groups: low, intermediate, and high risk.
Previously, two of the predictive factors closely involved
in predicting the molecular response in CMLwere identified.
Thefirst such factor is IC50. In 2005,White et al. [130] studied
inhibitory concentration 50% (IC50imatinib) as a predictor of
molecular response for CML patients. The results demon-
strate that IC50imatinib is a powerful pretreatment predictor
[131]. The second factor is the activity of organic cation
transporter 1 (OCT-1). There are two functions for OCT
proteins, which are cellular uptake and excretion of a number
of exogenous and endogenous cationic and uncharged sub-
stances. The OCT-1 protein activity (OA) can be measured
by uptake in the presence and absence of a specific OCT-
1 inhibitor. It has been found that patients with high OA
have a better molecular response than patients with low OA;
therefore, OA is considered a predictive factor for response
to Imatinib, but not for Nilotinib or Dasatinib [131, 132].
White et al. propose [133] that, in CML patients treated with
Imatinib, the use of OA pretherapy was a predictor for long-
term resistance risk and could be used to individualize dosage
strategies. Thus, involving OA to estimate the response could
lead to better results, but only for Imatinib therapy. A
recent study has investigated the possible association between
molecular response and a number of factors such as Sokal
score, age, sex, and Imatinib dose [134]. It was also found that
being female is a strong predictor [134]. A recent review of
biomarkers that determine prognosis in CML also presented
a list of prognostic indicators at diagnosis, such as the three
scoring systems, BCR-ABL1 transcript type, and OA [135].
Another factor is the BCR-ABL transcript type; CML patients
with the b3a2 BCR-ABL1 transcript type, compared to those
with the b2a2 transcript type, demonstrate greater survival
rates, while CML patients with the p190 transcript type are
classified as high risk [136, 137].
In practice, clinicians aim to treat individual CML
patients with the most beneficial therapy. This can be
made possible by using accurate risk assessment methods
at diagnosis. When there is any doubt about either the
diagnosis or the recommended treatment, a second opinion
is often sought before considering any treatment. The need
for multiple prognostic scores can occur frequently in a
complex problem that has multiple independent experts with
varying expertise. When developing prognostic scores have
different patient populations, each score can capture different
knowledge. There are two general major objectives for com-
bining prognostic scores: first, one prognostic score enhances
the decision of another one; and second, it increases the
reliability of the final decision. However, integrating multiple
prognostic scores could generate conflict in decisions and
may not be sufficient to make a final decision.
It is important that clinicians are comfortable with a
wide range of prognostic scores that will help to identify risk
category because a conflict between scores may be observed
in some patients. Consistency is defined as a score that does
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not contradict other prognostic scores. Consistency among
prognostic scores can increase clinicians’ trust, as they rely
on such results to make appropriate treatment decisions. It is
important to study and understand the consistency of scores
to help clinicians categorize patients into suitable risk groups
and subsequently make better therapeutic decisions.
In light of the aforementioned aspects, it is necessary
to conduct a study that can contribute to the CML medical
field by solving the previous issues. Using machine-learning
techniques and fusion techniques to address these problems
could produce promising results. The first proposed solution
is to build a personalized medicine support system as a
predictive model to combine strong molecular, clinical data,
and predictive assays for CML patients that could probably
predict an individual molecular response. Moreover, predict-
ing an individual response leads to predictingwarning groups
for eachTKI. Froma computer-science perspective, the above
issues could be resolved by using a machine-learning algo-
rithm that combines the most effective predictive indicators
to predict the outcomes for each TKI, based on existing
clinical profiles for individual CML patient characteristics.
The main goal of this review is to improve the ability to
manage CML disease in individual CML patients. Therefore,
CML is an example of a research opportunity to predict
the molecular response to TKI treatment. Using intelligent
computing techniques could bring about promising results
for CML patients.
3.5. Based on the Task. Most of the studies that usedmachine
learning and data mining incorporated two major tasks:
feature selection and classification (Figure 5). Although
dissimilar feature-selection algorithms may possibly choose
dissimilar pertinent genes or diverse numbers of relevant
genes or bring about different levels of classification precision
[138], feature selection can utilize observations and functions
to obtain dimensions for exploring optimal solutions [139].
In addition, selection of a subset in a classifier reduces the
computational time and costs of study, thereby increasing
classification accuracy.
Many studies [53, 89, 91, 103, 105, 112, 118] used classifi-
cation algorithms without feature-selection techniques. Since
cancer tumors are highly diverse in their genetic patterns and
progressions, DNA arrays provide a platform to obtain the
best measurements and observations, helping assign objec-
tives to one relevant feature set and hence contributing to
precise convergence toward optimal results [140]. However,
some researchers [42–44, 82, 86, 87, 94, 96–99, 104, 108, 113,
115, 122, 141, 142] applied two common methods in feature
selection: filter and wrapper approaches with classification
algorithms. Considering feature-selection techniques is an
essential preprocessing method mandated for classification
processes [103].
Knowledge extraction or acquisition has been a great
challenge for researchers, as they exhibit unusual character-
istics in many different genes relative to the number of tumor
samples. AML acquires a similar appearance to ALL, which
makes it nearly impossible for researchers to distinguish
between synonymous patterns. However, Cho et al. [143]

































































Figure 5: Summary of the frequency of studies based on the task.
by means of gene-expression data. They used discriminant
partial least squares and linear discriminant analysis to
differentiate between acute leukaemia subtypes. They found
that these methods offered a satisfactory level of precision.
They concluded that the suggestedmethod builds the optimal
classifier made up of a highly accurate, small-size predictor.
Using multiple algorithms for knowledge extraction and
classification has not attracted much interest from leukaemia
researchers in previous studies [45, 140, 144]. Cho and Won
[86] were of the view that conventional machine learning
is incapable of delivering accurate information. For this
reason, they developed a novel ensemble machine-learning
approach for microarray classification. Results indicated
that the ensemble machine-learning approaches accuracy of
almost 97% in leukaemia classification, which makes it a
better alternative to basic machine-learning methods.
Among the 55 studies, three groups of researchers [45,
121, 140] built decision support systems, whose subfunctions
included multiple tasks. The first decision support system
[45] was built to support leukaemia diagnosis using exon
array analysis. The system combined intelligent techniques,
such as preprocessing and data-filtering techniques, clus-
tering for classifying patients, and extraction of knowledge
techniques. The authors suggested that further study of
bone marrow or blood samples may assist in diagnosis of
leukaemia stages. The second study [140] was conducted
to extract decision rules using a developed SVM. This
study comprised carrying out multiple tasks, including data
fusion, feature selection, making a prediction model based
on gene-expression data, and knowledge extraction.The third
study [121] involved developing decision support to identify
unhealthy ALL cells using feature-selection techniques with
SVM.
From the review of studies based on the task, the need
for personalized medicine in CML results in multiple active
TKI therapies as molecular targeted therapy available for
CML, multiple strategies utilized for frontline CML therapy,
BioMed Research International 15
heterogeneity in responses, and multiple prognostic scores
and predictive assays.
Therapy takes the form of two major strategies: (i)
frontline Imatinib or (ii) frontline second-generation TKIs
such as Nilotinib or Dasatinib [4]. Despite the remarkable
increase in the survival of CML patients treated with Ima-
tinib, some patients discontinue Imatinib therapy due to
intolerance, resistance, or progression. In the IRIS [64] trial,
it is demonstrated that variations in molecular response at
12 and 18 months of Imatinib was due to, in about 40%
of cases, discontinuing Imatinib because of intolerance or
resistance and due to further progression observed in 7% of
CML patients.
Hematologic, cytogenetic, and molecular strategies for
monitoring patient responses to therapies are used by Euro-
pean LeukaemiaNet [145]. To monitor molecular response,
RQ-PCR, which is a sensitive technique, is used to quantify
the level of BCR-ABL1 mRNA transcripts in the peripheral
blood of patients. Molecular monitoring is considered to be
a standard guide to clinical management in CML [146, 147].
The prediction of long-term molecular response to frontline
Imatinib in CML can help clinicians to select the best
treatment protocols for CML patients. Patients predicted not
to achieveMMR in the long termmight be better treated with
alternative frontline therapies, such as Nilotinib or Dasatinib.
Opportunities to improve individual care for CML patients
exist in the appropriate prediction of variation in treatment
response to support physicians in treatment decisions.
Prognostic scores are used to personalize CML patient
care by predicting responses to therapy. Although the prog-
nostic scores (Sokal, Hasford, EUTOS, and the ELTS scores)
remain in use today, they were developed either for iden-
tifying risk groups or for predicting cytogenetic response
to therapy, but not for molecular response. Although two
predictive assays, IC50imatinib and OCT-1 activity (OA), were
developed to predict molecular response, according to cur-
rent knowledge, a model using assays to predict molecular
response has not previously been considered. The combina-
tion of predictive assays results in greater predictive power
than that which each predictor provides alone [148, 149].
4. Conclusion
Modern oncology is experiencing a paradigm shift toward
personalized medicine, which aims to direct medical agents
toward the tumor site. The field of molecular medicine is
also undergoing transformational changes that are bringing
a much needed revolution in healthcare. This breakthrough
was made possible by technologies in genetic studies that
led to the sequencing of the human genome. An analysis of
biological samples fromwhole organisms has now beenmade
possible. In addition, this invention has given a new lease
of life to the treatment of cancer. However, the majority of
cancer patients have been shown to develop adverse drug
reactions due to overreliance on certain medications.
Intelligent techniques may be useful for clinicians in
decision-making, warning of specific problems or providing
treatment recommendations [150]. In that regard, it would
be worthwhile building personalized medicine support sys-
tem to work as predictive models that integrate molecular-
based data to predict cancer susceptibility, including risk
assessment, prediction of the probability of developing a type
of cancer prior to occurrence of the disease, prediction of
recurring cancer, and the prediction of cancer outcomes, such
as survivability, life expectancy, and response to therapy or
progression. This is highly advantageous since only a quarter
of cancer patients respond positively to the drugs prescribed
to them. Therefore, it is important to investigate the current
development of using molecular information in intelligent
models for personalized medicine.
The use of personalized medicine support systems
in medicine will bring a ray of hope to the treatment
of leukaemia. Other frontiers of personalized medicine
research, such as the role of genetics in infectious diseases,
proteomics, epigenetics, andmetabolomics, were not covered
by this review and are out of scope of this research. This
review was conducted based on current developments of
personalized medicine support systems, and a systematized
literature review was carried out on intelligent techniques
using molecular data analysis in leukaemia. Both sets of
literature led to identifying opportunities for further research
for personalizedmedicine support systems in one category of
leukaemia, namely, chronic myeloid leukaemia.We speculate
that this paper will assist health informatics and biomedical
and bioinformatics in order to answer specific technical
questions to help develop future research into leukaemia from
a technical perspective.
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